Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has earned an average recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $23.67.

Several analysts recently commented on the stock. KeyCorp initiated coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating for the company. BMO Capital Markets decreased their target price on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Acrivon Therapeutics in a research report on Thursday, November 14th. Finally, Cantor Fitzgerald assumed coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating on the stock.

Institutional Trading of Acrivon Therapeutics

Several hedge funds have recently modified their holdings of the business. American Century Companies Inc. raised its position in Acrivon Therapeutics by 14.2% in the fourth quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock worth $106,000 after acquiring an additional 2,186 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Acrivon Therapeutics by 7.6% in the 4th quarter. Renaissance Technologies LLC now owns 49,400 shares of the company’s stock valued at $297,000 after purchasing an additional 3,500 shares in the last quarter. Barclays PLC lifted its stake in shares of Acrivon Therapeutics by 14.4% in the fourth quarter. Barclays PLC now owns 38,091 shares of the company’s stock valued at $228,000 after purchasing an additional 4,785 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Acrivon Therapeutics by 20.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock worth $223,000 after buying an additional 6,239 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. purchased a new position in Acrivon Therapeutics in the fourth quarter valued at about $40,000. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Stock Up 10.2 %

ACRV opened at $5.85 on Friday. The firm has a market cap of $182.17 million, a price-to-earnings ratio of -2.17 and a beta of 0.77. Acrivon Therapeutics has a 52 week low of $3.71 and a 52 week high of $11.90. The business’s 50 day moving average is $5.93 and its two-hundred day moving average is $7.12.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.